CY1124667T1 - Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα - Google Patents

Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα

Info

Publication number
CY1124667T1
CY1124667T1 CY20211100889T CY211100889T CY1124667T1 CY 1124667 T1 CY1124667 T1 CY 1124667T1 CY 20211100889 T CY20211100889 T CY 20211100889T CY 211100889 T CY211100889 T CY 211100889T CY 1124667 T1 CY1124667 T1 CY 1124667T1
Authority
CY
Cyprus
Prior art keywords
modified rna
polypeptides
pharmaceutical form
rna encoding
encoding vegf
Prior art date
Application number
CY20211100889T
Other languages
Greek (el)
English (en)
Inventor
Leif Karlsson PARINDER
Regina Desirée FRITSCHE DANIELSON
Kenny Mikael HANSSON
Li Ming GAN
Ann-Charlotte Eva EGNELL
Kenneth Randall CHIEN
Jonathan Clarke
Original Assignee
Modernatx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx, Inc. filed Critical Modernatx, Inc.
Publication of CY1124667T1 publication Critical patent/CY1124667T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20211100889T 2016-06-07 2021-10-14 Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα CY1124667T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662346979P 2016-06-07 2016-06-07
US201662411091P 2016-10-21 2016-10-21
US201662432005P 2016-12-09 2016-12-09
PCT/US2017/036188 WO2017214175A1 (en) 2016-06-07 2017-06-06 Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto

Publications (1)

Publication Number Publication Date
CY1124667T1 true CY1124667T1 (el) 2022-07-22

Family

ID=59270113

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100889T CY1124667T1 (el) 2016-06-07 2021-10-14 Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα

Country Status (25)

Country Link
US (1) US11866475B2 (enExample)
EP (2) EP3464338B1 (enExample)
JP (3) JP6859369B2 (enExample)
KR (4) KR102552543B1 (enExample)
CN (2) CN116606861A (enExample)
AU (2) AU2017277277B2 (enExample)
CA (1) CA3026500A1 (enExample)
CY (1) CY1124667T1 (enExample)
DK (1) DK3464338T3 (enExample)
ES (1) ES2895421T3 (enExample)
HR (1) HRP20211569T1 (enExample)
HU (1) HUE056055T2 (enExample)
IL (1) IL263370A (enExample)
LT (1) LT3464338T (enExample)
MA (1) MA45172B1 (enExample)
MX (1) MX2018015110A (enExample)
PL (1) PL3464338T3 (enExample)
PT (1) PT3464338T (enExample)
RS (1) RS62556B1 (enExample)
RU (1) RU2756313C2 (enExample)
SG (2) SG10202012175YA (enExample)
SI (1) SI3464338T1 (enExample)
SM (1) SMT202100586T1 (enExample)
TW (2) TWI752036B (enExample)
WO (1) WO2017214175A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3464338T (pt) 2016-06-07 2021-10-19 Modernatx Inc Arn modificado que codifica polipéptidos vegf-a, formulações e respetivos usos
US11628227B2 (en) * 2017-07-05 2023-04-18 Wisconsin Alumni Research Foundation Mineral coated microparticles for gene delivery in chronic wound therapy
MA50522B1 (fr) * 2017-10-31 2022-09-30 Astrazeneca Ab 151 85 Soedertaelje Nanoparticules lipidiques pour l'administration d'un arn modifié codant pour un polypeptide vegf-a
CN114173826A (zh) * 2019-05-08 2022-03-11 阿斯利康(瑞典)有限公司 使用脂质纳米颗粒用于递送编码vegf-a多肽的经修饰的rna的方法和包含其的药物组合物
JP7345888B2 (ja) * 2021-06-17 2023-09-19 株式会社ニューギン 遊技機
WO2023061985A2 (en) * 2021-10-12 2023-04-20 Modernatx, Inc. Compositions comprising modified rna encoding vegf-a and methods of use
WO2023084013A1 (en) * 2021-11-12 2023-05-19 Modernatx, Inc. Compositions comprising modified rna encoding vegf-a and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
EP1863516A2 (en) 2005-02-08 2007-12-12 Board of Regents, The University of Texas System Compositions and methods involving mda-7 for the treatment of cancer
BRPI0920976A2 (pt) 2008-12-03 2015-08-18 Amorcyte Inc Composições que melhoram a perfusão da area de infarto e metodos de restauração da lesão vascular.
WO2010065671A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
WO2011069529A1 (en) * 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
CA2821622C (en) 2010-12-16 2019-09-03 Sprna Gmbh Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US10086043B2 (en) 2011-04-03 2018-10-02 The General Hospital Corporation Efficient protein expression in vivo using modified RNA (MOD-RNA)
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
AU2012358384A1 (en) 2011-12-21 2014-07-31 Moderna Therapeutics, Inc. Methods of increasing the viability or longevity of an organ or organ explant
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US20140275229A1 (en) * 2012-04-02 2014-09-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
US10258698B2 (en) * 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
SG10201801428RA (en) 2013-08-21 2018-03-28 Curevac Ag Method for increasing expression of rna-encoded proteins
CN110903398B (zh) * 2014-01-15 2023-08-15 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
PT3464338T (pt) 2016-06-07 2021-10-19 Modernatx Inc Arn modificado que codifica polipéptidos vegf-a, formulações e respetivos usos
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
MX389934B (es) 2016-12-09 2025-03-20 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos.
MA50522B1 (fr) 2017-10-31 2022-09-30 Astrazeneca Ab 151 85 Soedertaelje Nanoparticules lipidiques pour l'administration d'un arn modifié codant pour un polypeptide vegf-a
WO2020227642A1 (en) 2019-05-08 2020-11-12 Modernatx, Inc. Compositions for skin and wounds and methods of use thereof

Also Published As

Publication number Publication date
KR102494499B1 (ko) 2023-01-31
SG11201810816QA (en) 2018-12-28
AU2017277277B2 (en) 2023-05-04
SG10202012175YA (en) 2021-01-28
RU2756313C2 (ru) 2021-09-29
MX2018015110A (es) 2019-09-06
TWI752036B (zh) 2022-01-11
MA45172B1 (fr) 2021-11-30
JP2021100961A (ja) 2021-07-08
AU2017277277A1 (en) 2019-01-03
DK3464338T3 (da) 2021-10-18
CN109790207B (zh) 2023-06-20
KR20220038819A (ko) 2022-03-29
KR102376245B1 (ko) 2022-03-21
EP3464338B1 (en) 2021-07-21
EP3971204A1 (en) 2022-03-23
RU2018147229A (ru) 2020-07-10
SI3464338T1 (sl) 2022-02-28
RU2018147229A3 (enExample) 2020-09-23
MA45172A (fr) 2019-04-10
JP2019521976A (ja) 2019-08-08
TWI818375B (zh) 2023-10-11
LT3464338T (lt) 2022-01-10
WO2017214175A1 (en) 2017-12-14
KR20230107891A (ko) 2023-07-18
PL3464338T3 (pl) 2021-12-27
EP3464338A1 (en) 2019-04-10
TW202218670A (zh) 2022-05-16
CN116606861A (zh) 2023-08-18
KR102552543B1 (ko) 2023-07-06
CA3026500A1 (en) 2017-12-14
RS62556B1 (sr) 2021-12-31
ES2895421T3 (es) 2022-02-21
JP6859369B2 (ja) 2021-04-14
HUE056055T2 (hu) 2022-01-28
JP7167226B2 (ja) 2022-11-08
PT3464338T (pt) 2021-10-19
US20200407411A1 (en) 2020-12-31
KR20230019505A (ko) 2023-02-08
HRP20211569T1 (hr) 2022-01-21
US11866475B2 (en) 2024-01-09
AU2023208200A1 (en) 2023-08-17
IL263370A (en) 2018-12-31
SMT202100586T1 (it) 2021-11-12
CN109790207A (zh) 2019-05-21
KR20190039066A (ko) 2019-04-10
JP2023011733A (ja) 2023-01-24
TW201808325A (zh) 2018-03-16

Similar Documents

Publication Publication Date Title
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
CY1124867T1 (el) Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
CY1125423T1 (el) Μεθοδος in vitro διαφοροποιησης των μεσεγκεφαλικων ντοπαμινεργικων(mda)νευρωνων
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1124698T1 (el) Πρωτεϊνη δεσμευσης il-18 (il-18bp) σε φλεγμονωδεις νοσους
CY1122948T1 (el) 1η-πυρρολο[2,3-c]πυριδιν-7(6η)-ονες και πυραζολο[3,4-c]πυριδιν-7(6η)-ονες ως αναστολεις των βετ πρωτεϊνων
CY1123697T1 (el) Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
CY1123746T1 (el) Ανθρωποποιημενα tau αντισωματα σε νοσο του alzheimer
CY1123925T1 (el) Μια νεα μορφη il33, μεταλλαγμενες μορφες της il33, αντισωματα, δοκιμασιες και μεθοδοι χρησης των ιδιων
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
BR112019005587A2 (pt) proteínas de ligação recombinantes e sua utilização
EA201890006A1 (ru) Применение экзосом для лечения болезни
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA202090919A1 (ru) Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a
CY1120862T1 (el) Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων
DOP2018000245A (es) Proteinas de fusion gdf15 y usos de estas
EA201792441A2 (ru) Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном
CY1124704T1 (el) Παραγωγα sobetirome
CY1122818T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-αλκυλ-8-αμινο-2-οξο-1,3-διαζα- σπε1ρο-[4.5]-δεκανιου
CY1120740T1 (el) Βελτιωμενα ευλογοϊικα εμβολια
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
CY1124727T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
MX2018015110A (es) Arn modificado que codifica polipeptidos de vegf-a. formulaciones y usos relacionados con los mismos.
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).